Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth
Disclosed herein are methods and compositions comprising placental adherent stromal cells, conditioned media derived from a cultured placental ASC, lysates thereof, and fractions thereof, for treating a skin condition (e.g. a compromised skin barrier, acne, wrinkles, hyper/hypo-pigmentation, dryness, elastosis); increasing skin volume, and preventing or treating alopecia and related conditions.
1 . A method for treating or ameliorating a skin condition in a subject, where said skin condition is selected from the group consisting of wrinkling, skin aging, reduced skin elasticity, and a compromised skin barrier, comprising administering a composition that comprises a conditioned medium (CM) of a cultured placental adherent stromal cell (ASC), thereby treating or ameliorating a skin condition.
2 . The method of claim 1 , where said skin condition is a compromised skin barrier.
3 . The method of claim 2 , wherein said compromised skin barrier is a side effect of a facial treatment.
4 . The method of claim 2 , wherein said compromised skin barrier is a side effect of a laser treatment.
5 . The method of claim 2 , wherein said compromised skin barrier is a side effect of a micro-needling treatment.
6 . The method of claim 2 , wherein said compromised skin barrier is a side effect of a chemical peel or mesotherapy.
7 . The method of claim 1 , where said skin condition is wrinkling.
8 . The method of claim 1 , where said skin condition is skin aging.
9 . The method of claim 1 , where said skin condition is reduced skin elasticity.
10 . The method of claim 1 , wherein said composition is a cosmetic serum formulation.
11 . The method of claim 1 , wherein said composition is a foam.
12 . The method of claim 1 , wherein said composition is a cream.
13 . The method of claim 1 , wherein said placental ASC have been incubated on a 3D substrate.
14 . The method of claim 54 , wherein said placental ASC have been incubated in a bioreactor.
15 . The method of claim 1 , wherein said ASC express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.
16 . The method of claim 15 , wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD11 b, CD14, CD19, and CD34.
17 . The method of claim 15 , wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD34, CD39, and CD106.
18 . The method of claim 17 , wherein more than 50% of said ASC express CD200.